Identification of HLA-DRB1 association to adalimumab immunogenicity.

about

Identification of HLA-DRB1 association to adalimumab immunogenicity.

Item

http://www.wikidata.org/entity/Q55284744

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Identification of HLA-DRB1 association to adalimumab immunogenicity.

@en

Identification of HLA-DRB1 association to adalimumab immunogenicity.

@nl

type

Item

label

Identification of HLA-DRB1 association to adalimumab immunogenicity.

@en

Identification of HLA-DRB1 association to adalimumab immunogenicity.

@nl

prefLabel

Identification of HLA-DRB1 association to adalimumab immunogenicity.

@en

Identification of HLA-DRB1 association to adalimumab immunogenicity.

@nl

P1476

Identification of HLA-DRB1 association to adalimumab immunogenicity.

@en

P2093

Ahmed Nader

http://www.w3.org/2001/XMLSchema#string

Jacob Degner

http://www.w3.org/2001/XMLSchema#string

Jeffrey F Waring

http://www.w3.org/2001/XMLSchema#string

Justin Wade Davis

http://www.w3.org/2001/XMLSchema#string

Kenneth B Idler

http://www.w3.org/2001/XMLSchema#string

Nael M Mostafa

http://www.w3.org/2001/XMLSchema#string

P2860

Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice

Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View

Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis

MHC associations with clinical and autoantibody manifestations in European SLE.

Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial

Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis.

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.

HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis.

Hormonal replacement therapy (HRT) in postmenopause: a reappraisal.

Pathogenesis and pharmacotherapy of Hidradenitis suppurativa.

P304

e0195325

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0195325

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mohan Liu

P577

2018-04-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29614084

http://www.w3.org/2001/XMLSchema#string

P921

adalimumab

P932

5882140

http://www.w3.org/2001/XMLSchema#string